Trade Names:Donnatal- Tablets 0.0194 mg atropine sulfate/0.0065 mg scopolamine hydrobromide/0.1037 mg hyoscyamine sulfate/16.2 mg phenobarbital- Elixir 0.0194 mg atropine sulfate/0.0065 mg scopolamine hydrobromide/0.1037 mg hyoscyamine sulfate/16.2 mg phenobarbital
Trade Names:Donnatal Extentabs- Tablets, extended-release 0.0582 mg atropine sulfate/0.0195 mg scopolamine hydrobromide/0.3111 mg hyoscyamine sulfate/48.6 mg phenobarbital
Promotes peripheral anticholinergic/antispasmodic action (decreases GI motility); provides mild sedation.
Possibly effective for treatment of irritable bowel syndrome and acute enterocolitis. Also may be useful as adjunctive therapy for duodenal ulcer.
Glaucoma; obstructive uropathy; obstructive disease of the GI tract; paralytic ileus; intestinal atony in elderly or debilitated patient; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; hepatic or renal disease; tachycardia; myocardial ischemia; unstable CV status in acute hemorrhage; myasthenia gravis; acute intermittent porphyrinuria.
PO 1 to 2 tablets 3 to 4 times daily; 1 extended-release tablet every 12 h; 5 to 10 mL elixir 3 to 4 times daily according to condition and severity of symptoms.Children
PO 0.5 to 5 mL elixir every 4 to 6 h, according to body weight.
Store in a cool, dry place.
Anticoagulant effects may be decreased.Anticholinergic agents
Additive anticholinergic effects.Haloperidol
Worsened schizophrenic symptoms; decreased haloperidol concentrations.Phenothiazines
Decreased antipsychotic effects and increased anticholinergic effects may occur.
None well documented.
Bradycardia; flushing; palpitations; tachycardia.
CNS stimulation (restlessness, tremor); confusion; dizziness; drowsiness; fever (especially in children); headache; insomnia; mental confusion or excitement (especially in the elderly, even with small doses); nervousness; psychosis; weakness.
Urticaria and other dermal manifestations of allergic reaction.
Altered taste perception; blurred vision; cycloplegia; dilated pupils; increased IOP; mydriasis; nasal congestion; photophobia.
bloated feeling; constipation; dysphagia; heartburn; nausea; paralytic ileus; vomiting; xerostomia.
Impotence; urinary hesitancy and retention.
Decreased sweating; severe allergic reactions, including anaphylaxis; suppression of lactation.
Category C .
If possible, do not use.
May react with agitation, drowsiness, and other untoward manifestations even with small doses.
Used with caution in patients with neuropathy, hepatic or renal disease, hyperthyroidism, coronary artery disease, CHF, arrhythmias, hypertension, or tachycardia. May complicate gastric ulcer treatment.
May be habit forming; when possible, not given to addiction-prone individual.
May be symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy and, therefore, may serve as contraindication.
Can occur in presence of high ambient temperature because of interference with normal sweating.
May produce drowsiness, dizziness, or blurred vision.
Dry mouth, thirst, vomiting, nausea, abdominal distention, CNS stimulation, delirium, drowsiness, restlessness, stupor, fever, seizures, hallucinations, convulsions, coma, “flat” EEG, circulatory failure, tachycardia, weak pulse, hypertension, hypotension, respiratory depression, palpitations, arrhythmias, urinary urgency, blurred vision, dilated pupils, photophobia, rash, dry and hot skin.
Copyright © 2009 Wolters Kluwer Health.